Tumor antigens for determining cancer therapy
The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
1. A method for treating triple negative breast cancer in a patient comprising
a) determining the expression pattern of a set of tumor antigens in a sample from the patient, wherein the set of tumor antigens comprises CXorf61 and preferentially expressed antigen in melanoma (PRAME);
b) diagnosing the patient as needing a cancer therapy regimen based on the determined expression pattern of CXorf61 and PRAME; and
c) treating the patient with an immunotherapeutic that targets those tumor antigens selected from the set of tumor antigens expressed in the patient.
2. The method of claim 1 wherein the set of tumor antigens further comprises cancer antigen 1 (CAGE1).
3. The method of claim 1 wherein the expression pattern is determined in a sample obtained from a triple negative breast cancer patient.
4. The method of claim 3 wherein the sample comprises cancer cells.
5. The method of claim 1 wherein determining the expression pattern comprises a quantitative and/or qualitative determination of the expression of the tumor antigens.
6. The method of claim 1 wherein determining the expression pattern comprises determining the expression of RNA and/or protein of the tumor antigens.
7. The method of claim 1 wherein the immunotherapeutic provides one or more T cell epitopes of each of those tumor antigens of the set of tumor antigens which are expressed in cancer cells of the patient.
8. The method of claim 1 wherein the immunotherapeutic is an RNA vaccine.
9. A method for preventing or treating triple negative breast cancer in a patient comprising administering to said patient an immunotherapeutic targeting each tumor antigen of a set of tumor antigens, wherein the set of tumor antigens comprises CXorf61 and preferentially expressed antigen in melanoma (PRAME).
10. The method of claim 9 wherein the set of tumor antigens further comprises cancer antigen 1 (CAGE1).
11. The method of claim 9 which comprises inducing an immune response in the patient against each tumor antigen of the set of tumor antigens.
12. The method of claim 11 wherein the immune response comprises a cellular response.
13. The method of claim 12 wherein the immunotherapeutic is a vaccine and the cellular response is induced by administering the vaccine providing one or more T cell epitopes of each tumor antigen of the set of tumor antigens to the patient.
14. The method of claim 13 wherein the one or more T cell epitopes are comprised in the vaccine in one or more peptides or polypeptides wherein said one or more peptides or polypeptides following administration are processed to produce the one or more T cell epitopes.
15. The method of claim 13 wherein the vaccine is an RNA vaccine.